Table 1.

Patient characteristics before LCIG infusion and change in gait parameters following LCIG infusion

	Patient 1	Patient 2	Patient 3
Age at PD diagnosis (years)	51	46	46
Age at STN DBS (years)	58	53	58
Nature of gait dysfunction post-DBS	FOG, slowing of gait, foot dystonia, falls	FOG, slowing of gait, left ankle dystonia	FOG, slowing of gait, left foot dystonia
Maximum medical therapy for gait dysfunction pre-LCIG	Levodopa 800 mg/day; botulinum toxin lower leg	Levodopa 600 mg/day; rotigotine 4 mg/day	Levodopa 800 mg/day; pramipexole 0.75 mg/day
Time post-DBS of LCIG initiation (years)	9	8	8
Maintenance LCIG infusion rate (mg levodopa per hour)	40	52	70
Walking time and distance pre-LCIG	12.5 sec† (12, 13); 10 m	16 sec* (22, 10); 8 m	11 sec† (11, 11); 10 m
Walking time and distance post-LCIG	9 sec† (8, 10); 10 m	9.5 sec* (11, 8); 8 m	9.5 sec† (9, 10); 10 m
180-degree turn time pre-LCIG (seconds)	3	4	4
180-degree turn time post-LCIG (seconds)	2	2	3
Time on LCIG at time of gait assessment (months)	6	8	23
Time on LCIG at time of writing (months)	36	37	31

^*in the case of patient 2, walking times are the mean of (a) a sit-to-stand then 8 m walk and (b) the 8 m return walk. The absolute times of the two segments measured are shown in brackets after the mean;

^†walking times for patients 1 and 3 are the mean of two 10 m walk trials, recorded one after the other. The absolute times of the two trials are shown in brackets after the mean.

LCIG: levodopa-carbidopa intestinal gel, PD: Parkinson’s disease; STN: subthalamic, DBS: deep brain stimulation, FOG: freezing of gait.